Randomized comparison of two different treatment concepts in newly diagnosed acute promyelocytic leukemia (APL). A randomized study for comparison of the effects of ATRA and intensified double induction therapy incorporating high dose ara-C followed by TAD consolidation and cyclic maintenance therapy (AMLCG concept) and induction therapy with ATRA and idarubicin (AIDA) followed by three anthracyclin/ATRA- based consloidation courses and maintenance therapy (PETHEMA conzept).

Trial Profile

Randomized comparison of two different treatment concepts in newly diagnosed acute promyelocytic leukemia (APL). A randomized study for comparison of the effects of ATRA and intensified double induction therapy incorporating high dose ara-C followed by TAD consolidation and cyclic maintenance therapy (AMLCG concept) and induction therapy with ATRA and idarubicin (AIDA) followed by three anthracyclin/ATRA- based consloidation courses and maintenance therapy (PETHEMA conzept).

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2016

At a glance

  • Drugs Tretinoin (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Daunorubicin; Idarubicin; Mercaptopurine; Methotrexate; Mitoxantrone; Tioguanine
  • Indications Acute promyelocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top